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OBJECTIVES This study was designed to determine whether antibody neutralization of the adhesion
protein P-selectin would prevent neutrophil activation and reduce myocardial reperfusion
injury.
BACKGROUND Although inhibition of P-selectin markedly reduces short-term myocardial injury after
ischemia and reperfusion, it is unknown whether it can provide meaningful long-term
protection and preserve left ventricular function.
METHODS Closed-chest dogs underwent 90 min left anterior descending coronary artery occlusion and
48 h reperfusion, and were randomized to 1) a treatment group (n 5 11) receiving 1 mg/kg
of the blocking anti–P-selectin antibody PB1.3, or 2) a control group receiving 1 mg/kg
PNB1.6 (nonblocking antibody against P-selectin, n 5 7) or an equivalent volume of saline
(n 5 2) 10 min before reperfusion. Infarct size was assessed postmortem by triphenyl
tetrazolium chloride staining. Contrast left ventriculography was used to measure left
ventricular function. Activation of circulating polymorphonuclear neutrophils (PMNs) was
assessed by an increase in surface CD18 expression.
RESULTS Neutrophil activation was observed at 30 min after reperfusion in the control group, but was
abolished in the treatment group. Infarct size was reduced about 25% in the treatment group
after controlling for variations in ischemic blood flow (p 5 0.003, by analysis of covariance).
However, this protective effect was not associated with preservation of blood flow to the
ischemic–reperfused myocardium, nor with any improvement in global or regional left
ventricular function.
CONCLUSIONS The anti–P-selectin antibody PB1.3 prevented early PMN activation, but had only a modest
long-term infarct-limiting effect over 48 h reperfusion. Adhesion molecules other than
P-selectin may mediate delayed PMN activation and accumulation in reperfused myocar-
dium. (J Am Coll Cardiol 1999;34:280–8) © 1999 by the American College of Cardiology
P-selectin (GMP-140, CD62) localizes in alpha-granules of
platelets and in Weibel-Palade bodies of endothelial cells
(1,2), and distributes to the endothelial cell plasma mem-
brane rapidly after exposure to histamine (1), thrombin (3)
or oxygen radicals (4) in vitro, or after ischemia–reperfusion
of various tissues in vivo (5,6). P-selectin is believed to
mediate polymorphonuclear neutrophil (PMN) rolling in
vivo (7), thereby facilitating CD11/CD18-mediated attach-
ment of PMNs to endothelial cells and PMN emigration
from the vascular lumen (3,8–11). P-selectin appears to
tether PMNs to promote juxtacrine activation of CD11/
CD18 integrins by interaction between platelet-activating
factor (PAF) and its PMN receptor (12). Although the
dependence of CD11/CD18 up-regulation on P-selectin
has been demonstrated in vitro, no studies have been done
to show that the same dependence occurs in vivo in the
setting of ischemia–reperfusion.
If P-selectin is an important facilitator of PMN activa-
tion, immunoneutralization of P-selectin should prevent
infiltration of PMNs into ischemic–reperfused tissues and
thereby block PMN-induced tissue injury. On the basis of
this hypothesis, the anti–P-selectin antibody PB1.3 has
been shown to markedly reduce infarct size in cats and dogs
with 1.5- to 2-h coronary artery occlusion and short-term
reperfusion of up to 4.5 h (13,14). Immunohistologic
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studies have shown that P-selectin is expressed only tran-
siently after ischemia–reperfusion and is much less evident
after 2 h of reperfusion (6). Although this finding might
suggest that transient inhibition of P-selectin should result
in sustained protection against PMN-mediated reperfusion
injury, other adhesion molecules become expressed and may
assume importance later after reperfusion, or other non–
adhesion-related mechanisms may account for delayed ac-
cumulation of PMNs and tissue injury. P-selectin knockout
mice have been found to have total absence of leukocyte
rolling in mesenteric venules, but are able, nevertheless, to
mobilize nearly normal numbers of PMNs to the peritoneal
cavity during experimentally induced inflammation, albeit in
a delayed fashion (15).
The current study was, therefore, designed to investigate
whether P-selectin plays a role in PMN activation after
myocardial ischemia–reperfusion and whether inhibition of
P-selectin results in a sustained and meaningful reduction of
myocardial injury after 48 h of reperfusion. A closed-chest
canine infarct model was used to avoid the inflammatory
response associated with surgery, and the same anti–P-
selectin antibody was chosen that produced marked reduc-
tions of infarct size after short-term reperfusion in feline
and canine models (13,14).
METHODS
Surgical preparation. Adult female mongrel dogs, weigh-
ing 20 to 27 kg, were anesthetized with thiopental sodium
(20 to 30 mg/kg), intubated and ventilated with 0 to 2%
halothane, with the concentration adjusted to maintain a
stable arterial blood pressure. Through small skin incisions,
8-F vascular sheaths were placed aseptically in a femoral
vein and both femoral arteries, and 5,000 IU of heparin was
administered intravenously. Under fluoroscopy, a 6- or 7-F
pigtail catheter was inserted into the left ventricle for
injection of radiolabeled microspheres and contrast me-
dium. For coronary arterial occlusion, an angioplasty bal-
loon catheter with appropriate balloon diameter (2.5 to
3.5 mm) was advanced to the proximal left anterior de-
scending coronary artery (LAD) over a 0.014-in. (0.036 cm)
guide wire through a 7-F guiding catheter positioned in the
left coronary ostium. Femoral artery pressure and heart rate
were monitored continuously.
Experimental protocol. Dogs were subjected to LAD
occlusion for 90 min followed by 48 h reperfusion. Com-
plete LAD occlusion and reperfusion were confirmed an-
giographically after balloon inflation and deflation. The
angioplasty balloon and guiding catheters were removed
shortly after reperfusion. Ten minutes before reperfusion,
dogs were randomized to receive intravenous administration
of 1 mg/kg PB1.3 (a blocking anti–P-selectin antibody, n 5
11), or PNB1.6 (a nonblocking control anti–P-selectin
antibody, n 5 8, 1 mg/kg) or saline (n 5 2). After 3.5 h of
reperfusion, all catheters were removed, the femoral arteries
and veins were ligated, the incisions were closed and the
dogs were allowed to recover from anesthesia. At 48 h after
reperfusion, dogs were reanesthetized and intubated, and
repeat cannulation of the left ventricle and left coronary
ostium was performed via a femoral artery cutdown. The
chest was opened after acquiring hemodynamic, hemato-
logic, flow and angiographic data, and the heart was excised.
At baseline and 70 min after occlusion, and 10 min, 1 h,
3.5 h, 24 h and 48 h after reperfusion, blood samples were
withdrawn for measurement of circulating blood cell counts,
and hemodynamics were recorded.
Monoclonal antibodies. Monoclonal antibodies (mAbs)
PB1.3 (Cy1747) and PNB1.6, both of which were provided
pyrogen free by Cytel Corp. (San Diego, California), were
murine immunoglobulin (Ig) G1 monoclonal antibodies
raised against human P-selectin. PB1.3 has been shown to
block the interaction between P-selectin and its receptor in
various species (8,11,16–18), whereas PNB1.6 recognizes
but does not block P-selectin (5,13,18,19).
Assessment of cross-reactivity of PB1.3 to dog P-selectin.
Platelets were obtained by centrifugation of normal dog
blood with prostaglandinE1 (1 mmol/liter) added to reduce
in vitro platelet activation, and the pellet was resuspended in
Tyrode’s buffer. Aliquots of 50 3 106 platelets were acti-
vated with 25 mmol/liter thrombin receptor–activating pep-
tide (Ser-Phe-Leu-Leu-Arg-Asn) (20,21) (Bachem, Pennsyl-
vania) or 200 ng/ml of PAF (22) (Sigma Chemical Co., St.
Louis, Missouri) for 15 min to increase surface P-selectin
expression. After fixation with 3% formaldehyde, platelets
were washed, incubated with PB1.3 (0 to 100 mg/ml) for
15 min, washed again to remove free PB1.3 and incubated
with fluorescein isothiocynate–labeled goat antimouse IgG
(Sigma Chemical Co.) for 20 min. Cross-reactivity of
PB1.3 to dog P-selectin was assessed by flow cytometry
(FACScan, Becton Dickinson, Franklin Lakes, New Jer-
sey). For each experiment and each platelet activator, one
platelet sample was incubated with buffer containing sec-
ondary antibody but no PB1.3 to serve as a background for
the other samples in the group and to correct for any
nonspecific binding of PB1.3 to the platelet Fc receptor.
Assessment of mAb excess in plasma. Plasma samples
were obtained from 6 dogs in the PB1.3 group and 4 dogs
in the PNB1.6 group before, and 30 min, 3.5 h, 24 h and
Abbreviations and Acronyms
ANCOVA 5 analysis of covariance
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48 h after mAb administration. Plasma (250 ml) was
incubated with 250 ml of human platelet suspension con-
taining 50 million platelets activated with thrombin recep-
tor–activating peptide. The preparation of human platelets
was identical to that of dog platelets as described above. The
platelets were washed and incubated with fluorescein iso-
thiocyanate–labeled secondary antibody. The amount of
mAb in the plasma was assessed by the fluorescence inten-
sity on platelets. To obtain the fluorescence intensity result-
ing from a known concentration of mAb, 250 ml of
10-mg/ml PB1.3 instead of plasma was incubated with the
platelets.
Regional blood flow measurement. Radioactive micro-
spheres (15 mm diameter) labeled with 153Gd, 113Sn, 103Ru,
95Nb or 46Sc (DuPont, North Billerica, Massachusetts)
were used to measure myocardial blood flow. Two million
microspheres were injected into the left ventricle through
the pigtail catheter at baseline, after 75 min coronary
occlusion and at 3.5 h and 48 h after reperfusion. A
simultaneous reference blood sample was withdrawn from
an arterial sheath. After sacrifice, tissue samples were
counted with a scintillation counter, along with radionuclide
standards and background and reference blood samples.
Regional myocardial blood flow was calculated by standard
methods (23).
Estimation of risk, infarct and no-reflow region sizes.
After 48 h of reperfusion, the left ventricle was excised and
sectioned into five slices parallel to the atrioventricular ring.
Each slice was weighed, incubated in a 2% solution of
triphenyltetrazolium chloride for 30 min at 37°C to visualize
the infarct area and photographed. Area at risk was defined
by the regional blood flow during coronary occlusion. On
each slice, contiguous transmural myocardial sections (2 to
3 mm deep) were dissected from a region that covered the
whole area at risk. One transmural section was taken from
the nonischemic region in each slice. Each transmural
section was divided into five samples weighing 0.05 to 0.2 g
between endocardium and epicardium. Samples with blood
flow during occlusion less than 50% of transmural flow in
the nonischemic area were considered ischemic (24). The
no-reflow region was defined as myocardium with more
than 50% reduction of blood flow at 48 h of reperfusion
compared with the nonischemic area. The photographic
transparencies were projected and traced, and the location of
each tissue sample was marked and color coded. The masses
of infarct, area at risk and no-reflow area were quantified by
computerized planimetry of the appropriate areas in each
slice, multiplied by the weight of the slice and summed for
the entire left ventricle.
Assessment of PMN activation. Neutrophil activation
was assessed in dogs receiving PB1.3 or PNB1.6 by the
surface expression of CD18 on circulating neutrophils.
Blood samples were obtained at baseline, after 75 min
coronary occlusion and at 10 min, 30 min, 1 h, 2 h and 3.5 h
after reperfusion. Whole blood was incubated with a satu-
rating concentration (20 mg/ml) of R15.7, a murine mono-
clonal antibody against CD18 (Boehringer-Ingelheim
Pharmaceuticals, Ridgefield, Connecticut), for 30 min at
4°C. The cells were washed with phosphate-buffered saline
with 1% bovine serum albumin and incubated with a
saturating concentration of fluorescein-conjugated goat an-
timouse Ig (Tago, Burlingame, California) for 30 min at
4°C. Neutrophil isolation was accomplished by erythrocyte
lysis with whole blood lysing reagent (Coulter Immunology,
Hialeah, Florida). The cells were washed and fixed in 1%
paraformaldehyde. The mean channel fluorescence was
measured by flow cytometry after selective gating of viable
cells, as determined by log-forward versus log-lateral scatter.
Left ventriculography. Left ventriculograms were per-
formed at baseline, during occlusion and 10 min and 48 h
after reperfusion. Nonionic contrast medium was injected
into the left ventricle through the pigtail catheter at a speed
of 7 ml/s for 4 s, and images were recorded in the 20° right
anterior oblique projection at 30 frames per second. For
analysis, the end-diastolic and end-systolic ventricular con-
tours were digitized using an ImageComm System (Sunny-
vale, California). Ejection fraction was calculated by the
area–length method, assuming a prolate spheroid shape of
the left ventricle (25). The left ventricle was divided into five
regions of 20 chords each (anterobasal, midanterior, apical,
midinferior and inferobasal). The motion of each region was
represented by the shortening of the center chord expressed
as a percent of the perimeter length (26). The motion of the
wall corresponding to the LAD region was expressed as the
average of the center chord shortenings of the midanterior
and apical regions (anterior wall motion); wall motion in the
circumflex perfused region was expressed as the average of
the inferobasal and midinferior regions (inferior wall mo-
tion).
Myeloperoxidase assay. Transmural myocardial samples
weighing 0.5 to 1.0 g were obtained from both the center of
the area at risk and the normal area on a midventricular
slice. The samples were frozen and maintained at 270°C
immediately after counting microsphere radioactivity. The
activity of myeloperoxidase (MPO) was measured as previ-
ously described (27). Results were expressed as units of
MPO per 100 mg wet weight.
Statistical analysis. All data are presented as the mean 6
SEM. Hematologic, hemodynamic, flow and ejection frac-
tion variables during ischemia and reperfusion in control
and PB1.3 groups were compared by repeated measures
analysis of variance. Two-way analysis of variance, com-
bined with Dunnett’s post hoc test for multiple compari-
sons, was used to test for an overall difference between
groups for each variable, and for differences at each time
point within and between groups. Comparisons of infarct
size and tissue MPO were made by the Student t test. The
relation between infarct size and collateral blood flow was
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determined by linear regression analysis, and an analysis of
covariance (ANCOVA) was performed to determine
whether treatment effect was significant after controlling for
the influence of collateral blood flow. To test the hypothesis
that PB1.3 prevented early PMN activation, repeated mea-
sures analysis of variance with Dunnett’s post hoc test was
applied to determine the time points at which there were
significant differences in CD18 expression between groups
and in comparison with baseline within each group. Profile
analysis was also used to compare the two groups by
performing analysis of variance for the transformed variable
representing the difference in CD18 expression between
adjacent time points.
RESULTS
Of the 22 dogs undergoing LAD occlusion, one died before
randomization (at 20 min after occlusion) and one injected
with PNB1.6 died at 5 min after reperfusion because of
ventricular fibrillation. Accordingly, 20 dogs were used for
the data analyses. They were divided into two groups: the
PB1.3 group (n 5 11) and the control group (seven dogs
treated with PNB1.6 and two dogs given saline).
Antibody binding to P-selectin on activated platelets.
The affinity of PB1.3 to dog P-selectin was assessed by flow
cytometry of activated dog platelets. Mean channel fluores-
cence, representing the amount of bound PB1.3, increased
in a concentration-dependent manner (Fig. 1). Similar
results were observed when adenosine diphosphate or hy-
drogen peroxide was used as a platelet activator. A dose of
1 mg/kg PB1.3 was chosen for the in vivo studies, since this
dose resulted in a concentration of about 10 mg/ml in blood,
which was sufficient for near maximal binding (Fig. 1).
Assessment of mAb excess in plasma. Mean channel
fluorescence of human platelets incubated with plasma
samples acquired before and at 30 min, 3.5 h, 24 h and 48 h
after PB1.3 injection was 3 6 1, 358 6 13, 349 6 21, 333 6
20 and 343 6 17, respectively. Results at the same time
points before and after PNB1.6 injection were 22 6 4,
200 6 18, 231 6 17, 206 6 9 and 207 6 12, respectively.
Incubation of platelets with 10 mg/ml PB1.3 instead of
plasma resulted in a mean channel fluorescence of 386.
These data suggest that after injection, both PB1.3 and
PNB1.6 stayed in the circulation at a high concentration
throughout the 48-h experiment and that the dose of PB1.3
was sufficient to achieve near maximal P-selectin blockade.
Hemodynamics. Blood pressure decreased in both control
and PB1.3 groups after coronary occlusion. No significant
differences in blood pressure or heart rate were seen between
the two groups at any time point. Antibody injection
produced no hemodynamic effect.
Hematologic parameters. Leukocyte and neutrophil
counts were increased at 24 h reperfusion but returned
toward baseline levels at 48 h in both groups. Compared
with baseline, hematocrit and platelet count were decreased
at 48 h in both groups. Except for a lower hematocrit at
baseline in the PB1.3 group (39% vs. 45%, p , 0.05), there
were no significant differences between the two groups at
any time point in any hematologic parameter. Antibody in-
jection had no significant effect on any hematologic variable.
Regional myocardial blood flow. Myocardial blood flow
to endo-, mid- and epicardium in the ischemic-reperfused
region and transmural myocardium in the nonischemic
region is shown in Table 1. There were no significant
differences in blood flow between the two groups in any
region at any time point.
Infarct size. Infarct size expressed as a percent of the area
at risk was inversely related to transmural collateral flow in
both groups, and the regression line for the PB1.3 group
(y 5 54.3 2 5.1x, r 5 0.87) was shifted downwards
compared with that of the control group (y 5 66.4 2 4.4x,
r 5 0.91) (p 5 0.003 by ANCOVA) (Fig. 2), indicating
that both severity of ischemia and PB1.3 treatment contrib-
uted significantly to infarct size. The downward shift of the
regression line in the PB1.3 group was also observed when
infarct size was plotted against endo- or epicardial collateral
flow (p 5 0.005 for endocardial flow and p 5 0.012 for
epicardial collateral flow by ANCOVA). The average in-
farct size as a percent of area at risk was 47.7 6 7.3% in the
control group and 35.5 6 5.4% in the PB1.3 group (p 5
0.19), respectively, without adjustment for the severity of
ischemia. The transmural collateral flow and area at risk as
a percent of left ventricle in control and PB1.3 groups were
4.3 6 1.5 versus 3.7 6 0.9 ml/min/100 g and 25.4 6 2.4
versus 27.6 6 1.6%, respectively. The size of the no-reflow
area as a percent of the area at risk did not differ between the
two groups (26.6 6 4.1% in the control and 20.4 6 4.3% in
the PB1.3 group), consistent with the observation that
Figure 1. In vitro PB1.3 binding to dog platelets stimulated by
thrombin receptor–activating peptide (TRAP) or platelet-
activating factor (PAF). Mean channel fluorescence increased in a
concentration-dependent manner, indicating cross-reactivity of
PB1.3 to dog P-selectin.
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PB1.3 treatment did not attenuate the blood flow reduction
at 48 h reperfusion.
Effect of treatment with PB1.3 on PMN activation. In
the control group, mean channel fluorescence, representing
CD18 expression on circulating PMNs, significantly in-
creased at 30 min after reperfusion compared with the
PB1.3 group (113.7 6 5.6% vs. 96.1 6 4.0% of baseline
fluorescence, p , 0.01 by analysis of variance and Dunnett’s
post hoc test) and returned to the baseline level by 2 h (Fig.
3). CD18 expression on PMNs at 30 min after reperfusion
was correlated with the amount of ischemic myocardium,
represented by the area at risk as a percent of left ventricle,
in the control group (r 5 0.83) but not in the group
receiving PB1.3 (r 5 0.18) (Fig. 4). The time course of
CD18 expression was significantly different between the
two groups after 1 h reperfusion. In contrast to down-
regulation of CD18 in the control group, CD18 expression
on PMNs from dogs in the PB1.3 group showed significant
Figure 2. Relation between infarct size and the severity of isch-
emia in control (open circles) and PB1.3 antibody (closed circles)
groups. The regression line for PB1.3 was shifted significantly
downward (p 5 0.003 by analysis of covariance).
Figure 3. Time course of CD18 expression on circulating poly-
morphonuclear neutrophils (PMNs). In the control group, CD18
expression increased significantly at 30 min after reperfusion, and
returned to the baseline level by 2 h. However, treatment with
PB1.3 prevented up-regulation of CD18 at 30 min after reperfu-
sion. The curves were also significantly different after 1 h reper-
fusion by profile analysis.
Table 1. Myocardial Blood Flows in Control and PB1.3 Groups
Baseline Occlusion
Reperfusion
3.5 h 48 h
Ischemic-reperfused region
Endocardium
Control (n 5 9) 95.5 6 14.7 1.9 6 0.9* 35.2 6 7.3† 25.6 6 11.3*
PB1.3 (n 5 11) 75.4 6 8.3 1.2 6 0.5* 42.6 6 7.2* 26.4 6 4.1*
Midmyocardium
Control (n 5 9) 86.3 6 14.8 3.8 6 1.4* 42.1 6 10.5 35.6 6 12.4†
PB1.3 (n 5 11) 74.5 6 10.0 2.5 6 0.7* 35.3 6 4.9* 39.6 6 6.2*
Epicardium
Control (n 5 9) 74.4 6 12.1 6.9 6 2.3* 42.4 6 9.8 44.9 6 12.8
PB1.3 (n 5 11) 68.5 6 9.1 6.6 6 1.6* 36.4 6 4.7* 57.7 6 7.6
Nonischemic region
Transmural
Control (n 5 9) 96.0 6 14.1 63.5 6 5.7 60.2 6 7.7 75.6 6 12.8
PB1.3 (n 5 11) 92.3 6 10.7 75.8 6 6.5 54.7 6 5.0* 87.0 6 11.0
*p , 0.01 and †p , 0.05 compared with baseline in same group. Values are mean 6SEM for blood flow in ml/min/100 g.
Endocardial flow represents the average of the two most endocardial transmural samples, and epicardial flow is the average of
the two most epicardial samples. There were no significant differences between the two groups at any time point in any
parameter.
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up-regulation during this period (p 5 0.0026 vs. control
group by profile analysis), suggesting that delayed PMN
activation occurred in PB1.3-treated dogs.
Left ventricular function. Left ventricular ejection frac-
tion decreased markedly during coronary occlusion and
recovered slightly during reperfusion in both groups (Table
2). Similar changes were seen in left ventricular regional
chord shortening (Fig. 5). There were no significant differ-
ences between the two groups in either global or regional
left ventricular function at any time point.
Myocardial myeloperoxidase activity. The transmural
MPO activity in the ischemic–reperfused region was signif-
icantly increased compared with that in the nonischemic
region in both groups (0.71 6 0.20 vs. 0.03 6 0.01
U/100 mg in the control group, p , 0.01, and 0.59 6 0.14
vs. 0.04 6 0.01 U/100 mg in the PB1.3 group, p , 0.01).
There was no significant difference between the two groups.
DISCUSSION
Previous studies in animal models with myocardial ischemia
and up to 4.5 h reperfusion have demonstrated that admin-
istration of PB1.3 produces marked myocardial protection
with a reduction of infarct size of 50% or more (13,14,17).
Our study, which used 48 h reperfusion, demonstrated that
PB1.3 prevents the early activation of PMNs after reperfu-
sion, but reduces infarct size by only 25%, and does not
preserve global or regional left ventricular function or
prevent no-reflow in the infarcted myocardium. These
results suggest that inhibition of P-selectin may temporarily
prevent PMN-mediated reperfusion injury, but that full
myocardial protection is not sustained and ultimately the
benefit afforded by specific P-selectin blockade is rather
modest.
P-selectin and PMN activation. P-selectin facilitates
PMN activation on stimulated endothelium (12,28,29). By
binding to its PMN carbohydrate ligand, P-selectin tethers
the PMN for efficient juxtacrine activation by PAF, thereby
up-regulating CD11/CD18. In addition, purified P-selectin
can increase PMN CD11/CD18 adhesiveness, associated
with the appearance of an “activation” epitope (30).
Figure 4. CD18 expression on circulating neutrophils at 30 min
after reperfusion was correlated with the size of the area at risk in
the control group (open circles, y 5 58.8 1 1.6x, r 5 0.83) but not
in the group receiving PB1.3 (closed circles, y 5 86.9 1 0.3x, r 5
0.18). This suggests that the amount of neutrophil activation is
dependent on the amount of ischemic–reperfused myocardium and
that this activation can be prevented by PB1.3. LV 5 left ventricle.
Figure 5. Regional myocardial function assessed by left ventricu-
lography. Chord shortening was averaged in the anterior (infarct)
and posterior (control) regions. Wall motion was markedly re-
duced in the infarct region during occlusion and recovered slightly
after reperfusion (**p , 0.01 vs. baseline). However, there was no
significant difference in regional wall motion between the two
groups at any time point.
Table 2. Left Ventricular Ejection Fraction
Baseline Occlusion
Reperfusion
15 min 48 h
Control group (n 5 8) 50.9 6 1.8 31.3 6 3.1* 39.8 6 1.5† 35.5 6 3.1*
PB1.3 group (n 5 11) 50.6 6 1.9 29.5 6 1.3* 38.3 6 1.5* 36.1 6 2.4*
*p , 0.01 and †p , 0.05 compared with baseline in same group. Values are mean 6 SEM for left ventricular ejection fraction
in percent. There were no significant differences between the two groups at any time point.
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Selectin-mediated PMN rolling is a prerequisite for firm
adhesion dependent on CD11/CD18 and intercellular ad-
hesion molecule 1 (9,10,31). Soluble P-selectin or P-selectin
bound to platelets may also play a role (32). Ours is the first
study to demonstrate the dependence of CD18 up-
regulation on P-selectin in vivo in the setting of ischemia-
reperfusion.
P-selectin and myocardial reperfusion injury. Several
studies have reported very significant myocardial protection
by PB1.3 in large animal models with 1- to 2-h coronary
artery occlusion and 1- to 4.5-h reperfusion (13,14,17), with
infarct size reductions of 50% to 60% (13,14). Although we
found a statistically significant reduction in infarct size at
48 h in PB1.3-treated animals, the magnitude of myocardial
protection was modest and there was no concomitant
preservation of left ventricular function or perfusion of the
infarct region. Ours is the first study to examine the effects
of PB1.3 on myocardial reperfusion injury and left ventric-
ular function over such a long time period.
The dose of antibody we used was most likely sufficient,
since the same dose was used by others who reported more
favorable short-term results, and our own data demon-
strated that excess antibody was present in the blood for the
entire 48 h of reperfusion. Despite being developed against
human protein, PB1.3 demonstrated cross-reactivity with
P-selectin on dog platelets in our study, similar to previously
reported results (14,33). PB1.3 has been shown to effectively
inhibit P-selectin in a number of canine models of isch-
emia–reperfusion: PB1.3 prevented skeletal muscle no-
reflow (16), loss of coronary flow reserve and contractile
function (17), development of microvascular thrombi during
coronary hypoperfusion (33) and myocardial neutrophil
accumulation (14,17) and myocyte injury (14) in various
studies. In vitro, PB1.3 has been shown to reduce by .50%
the binding of canine neutrophils to thrombin-activated dog
coronary artery segments, whereas PNB1.6 was without
significant effect (14). Most recently, PB1.3, in a concen-
tration similar to the circulating blood concentration in our
study (10 mg/ml), was shown to completely inhibit the
thrombin-stimulated binding between canine neutrophils
and platelets mediated by P-selectin (33). In theory, being a
holoantibody, PB1.3 could have bound to platelet Fc
receptors rather than P-selectin. However, background
measurements included an Fc-containing IgG secondary
antibody without any PB1.3; binding of PB1.3 to nonacti-
vated platelets, which should have had Fc receptors but
minimal surface P-selectin, was insignificant.
The most likely reason for our findings is that we assessed
the results over 48 h reperfusion rather than the 1- to 4-h
period commonly used in acute studies. Analogous to our
results, Simpson et al. (34) showed that infusion of a
prostacyclin analogue for the first 2 h of reperfusion resulted
in a smaller infarct size at 6 h, but not at 72 h after
reperfusion. The beneficial effect of P-selectin immunoneu-
tralization may therefore be temporary rather than perma-
nent in myocardial ischemia–reperfusion injury.
P-selectin and other models of injury. PB1.3 has been
reported to attenuate complement-induced lung injury (18)
and systemic injury from hemorrhagic shock (35), both
acute models. However, Winn et al. (5) found that PB1.3
markedly reduced necrosis in the rabbit ear seven days after
a prolonged 6-h period of hypothermic ischemia. Immuno-
histologic studies showed positive staining for vascular
endothelial P-selectin for at least 4 h after reperfusion in
this model, considerably longer than the duration of expres-
sion found after 90 min of normothermic myocardial
ischemia (6).
Inflammation in P-selectin gene– deficient mice.
P-selectin deficient mice, despite an absence of detectable
P-selectin on platelets or vascular endothelium and virtual
absence of PMN rolling in mesenteric venules (15), never-
theless exhibit PMN rolling 4 h after injection of an
inflammatory irritant (36). After the intraperitoneal injec-
tion of thioglycollate to produce inflammation, the influx of
PMNs was markedly delayed in the P-selectin deficient
mice compared with that in the wild type. After 75 min, the
mutant mice had 25-fold fewer PMNs in the peritoneal
cavity, but by 4 h, there was only a two-fold difference, as
the P-selectin–deficient animals began to mobilize PMNs
(15).
In mice with P-selectin or L-selectin gene deficiencies,
PMN rolling in the cremaster muscle was dependent on
P-selectin for the first 60 min after surgical preparation, but
from 60 to 120 min rolling was L-selectin dependent (37).
Furthermore, rolling induced by tumor necrosis factor alpha
was largely dependent on L-selectin and was unaffected by
an anti–P-selectin antibody. These data suggest that
P-selectin mediates early targeting of PMNs to inflamma-
tory sites but that other mechanisms come into play to
mediate later PMN rolling and trapping as the expression of
P-selectin wanes.
P-selectin–independent mechanisms for PMN rolling.
Neutrophils may roll under conditions of reduced blood
flow independent of selectin molecules. Gaboury et al. (38)
showed that after a 50% reduction in shear rate in postcap-
illary venules, PAF induced a 10-fold increase in PMN
rolling and a five-fold increase in adhesion, both dependent
on CD18 and not selectins. Edema and vasoconstriction,
combined with release of chemotactic factors, could there-
fore reduce blood flow in the reperfused microcirculation,
and result in PMN trapping, adhesion and activation, all
mediated through interactions between CD11/CD18 and
intercellular adhesion molecule-1.
Prevention of reperfusion injury by blocking adhesion.
Neutralization of P-selectin represents an intrinsically at-
tractive approach for preventing PMN-mediated reperfu-
sion injury, because the tissues with up-regulated adhesion
molecules would be targeted. However, Kubes et al. (39)
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have argued that this approach is inefficient, because .90%
inhibition of PMN rolling is required to produce a modest
50% attenuation in PMN adhesion in postischemic venules.
We recently found that an anti-CD18 monoclonal anti-
body, R15.7, provided significantly better myocardial pro-
tection at 48 h reperfusion in the dog than did PB1.3 in the
current study (40). With R15.7 there was a 44% reduction
in infarct size, combined with significant preservation of
global and regional left ventricular function. However,
because this antibody inhibits all CD18-dependent cellular
functions throughout the body for up to 48 h, there is a
concern about possible increased susceptibility to infection
(41). Further studies will be needed to define the relative
risks and benefits of therapies given to prevent PMN-
mediated reperfusion injury in the heart and other organs.
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